April 2016
|
PRN1371, an irreversible, covalent inhibitor of FGFR1, 2, 3 and 4 is highly efficacious in preclinical tumor models
Venetsanakos E, Bradshaw JM, Goldstein DM, Leung K, Karr D, Gerritsen ME, Xing Y, LaStant J, Nunn PA, Shu J, Bommireddi A, Gourlay SG, Funk JO, Brameld KA.
Presented at American Association for Cancer Research Annual Meeting, New Orleans, LA, April 2016
|
March 2016
|
A New Treatment for Autoimmune Blistering Diseases: Efficacy of the Bruton’s Tyrosine Kinase (BTK) Inhibitor PRN473 in Canine Pemphigus Foliaceus
Outerbridge C, Goodale E, Varjonen K, Borjesson D, Murrell D, Bisconte A, Hill R, Masjedizadeh M, Gourlay SG, White S.
Presented at AAD 2016, Washington, DC, March 5, 2016
|
March 2016
|
Development of PRN1008, a novel, reversible covalent BTK inhibitor in clinical development for pemphigus
Murrell DF, Gourlay SG, Hill RJ, Bisconte A, Francesco M, Smith P, Karr D, Outerbridge C, Varjonen K, Goodale EC, Borjesson D, Werth VP, Nunn PA, White SD.
Presented at Medicinal Dermatology Society Annual Meeting, Washington, DC, March 3, 2016
|
March 2016
|
A New Treatment for Autoimmune Blistering Diseases: Efficacy of the Bruton’s Tyrosine Kinase (BTK) Inhibitor PRN473 in Canine Pemphigus Foliaceus
Outerbridge C, Goodale E, Varjonen K, Borjesson D, Murrell D, Bisconte A, Hill R, Masjedizadeh M, Gourlay SG, White S.
Presented at AAD 2016, Washington, DC, March 5, 2016
|
June 2015
|
A Phase 1 Clinical Trial of PRN1008, An Oral, Reversible, Covalent BTK Inhibitor Demonstrates Clinical Safety and Therapeutic Levels of BTK Occupancy Without Sustained Systemic Exposure
Smith PF, Krishnarajah, Nunn PA, Hill RJ, Karr D, Tam D, Masjedizadeh M, Gourlay SG.
Presented at EULAR 2015, Rome, June 13, 2015
|
June 2015
|
Preclinical Characterization of PRN1008, A Novel Reversible Covalent Inhibitor of BTK That Shows Efficacy In A Rat Model of Collagen-Induced Arthritis
Hill RJ, Bradshaw JM, Bisconte A, Tam D, Owens TD, Brameld KA, Smith PF, Funk JO, Goldstein DM, Nunn PA.
Presented at EULAR 2015, Rome, June 11, 2015
|
May 2015
|
Prolonged and tunable residence time using reversible covalent kinase inhibitors.
Bradshaw JM, McFarland JM, Paavilainen VO, Bisconte A, Tam D, Phan VT, Romanov S, Finkle D, Shu J, Patel V, Ton T, Li X, Loughhead DG, Nunn PA, Karr DE, Gerritsen ME, Funk JO, Owens TD, Verner E, Brameld KA, Hill RJ, Goldstein DM, Taunton J.
Nat. Chem Biol, 2015; May 25
|
May 2015
|
Efficacy in collagen induced arthritis models with a selective, reversible covalent Bruton’s Tyrosine Kinase (BTK) inhibitor PRN473 is driven by durable target occupancy rather than extended plasma exposure
Bisconte A, Hil RJ, Bradshaw JM, Verner E, Karr D, Finkle D, Brameld KA, Funk JO, Goldstein DM, Nunn PA.
Presented at The American Association of Immunologist Annual Meeting, New Orleans, LA, May 8-12, 2015
|
